Solutions To The AMR ‘Silent Pandemic’ Need More Than Just Lip Service
Antibiotics Innovators Bemoan Lack Of Incentives And Rewards In Face Of Ever-Growing AMR Threat
Executive Summary
With new antibiotics a rare commodity, persistently inadequate reimbursement for innovations and worthy but often piecemeal pilots, antimicrobial resistance has quietly risen to become a factor in well over a million deaths annually. Now that COVID-19 is not the all-encompassing threat to health it was until fairly recently, AMR is once again moving towards the center of attention. But properly funded actions and mindset changes are needed.